McKinsey’s Push For Class-Wide Opioid REMS Among Actions Targeted In Opioid Settlement

Consulting firm agrees to turn over tens of thousands of documents detailing its advice to Purdue, J&J, Endo and Mallinckrodt and pay $537m as part of a deal with 47 states.

McKinsey's opioid mess (photo illustration/shutterstock)
McKinsey's work with opioid manufacturers has caused a big mess • Source: photo illustration/Shutterstock

McKinsey & Co.’s settlement with state attorneys general reveals the scope of advice that they allege helped fuel the opioid epidemic. One notable action was the firm’s work with Purdue Pharma L.P. to develop an opioid risk evaluation and mitigation strategy (REMS).

A complaint by the Commonwealth of Massachusetts states that McKinsey “advised Purdue to ‘band together’ with other opioid manufacturers...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet